<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2024-6-53-60</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1666</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Ассоциация аллелей генов HLA-A, HLA-B, HLA-C, HLA-DRB1 c синдромом Шегрена и продукцией аутоантител к Ro/SSA и La/SSB</article-title><trans-title-group xml:lang="en"><trans-title>Association between the HLA-A, HLA-B, HLA-C and HLA-DRB1 gene alleles and Sjögren's syndrome with anti-Ro/SSA and anti-La/SSB autoantibodies production</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4906-7148</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусева</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Guseva</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ирина Анатольевна Гусева</p><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Irina Anatolievna Guseva</p><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><email xlink:type="simple">irrgus@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6943-2915</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чанышев</surname><given-names>М. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Chanyshev</surname><given-names>M. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>111123, Москва, ул. Новогиреевская, 3А</p></bio><bio xml:lang="en"><p>3A, Novogireevskaya Street, Moscow 111123</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8099-2107</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Торгашина</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Torgashina</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2388-1483</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Власенко</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vlasenko</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>111123, Москва, ул. Новогиреевская, 3А</p></bio><bio xml:lang="en"><p>3A, Novogireevskaya Street, Moscow 111123</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2314-1466</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хван</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Khvan</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7501-9185</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самаркина</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Samarkina</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-7981-5360</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шабатина</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shabatina</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5524-0296</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хафизов</surname><given-names>К. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Khafizov</surname><given-names>K. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>111123, Москва, ул. Новогиреевская, 3А</p></bio><bio xml:lang="en"><p>3A, Novogireevskaya Street, Moscow 111123</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФБУН «Центральный научно-исследовательский институт эпидемиологии» Роспотребнадзора</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central Research Institute of Epidemiology, Rospotrebnadzor</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>13</day><month>12</month><year>2024</year></pub-date><volume>18</volume><issue>6</issue><fpage>53</fpage><lpage>60</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гусева И.А., Чанышев М.Д., Торгашина А.В., Власенко Н.В., Хван Ю.И., Самаркина Е.Ю., Шабатина М.В., Хафизов К.Ф., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Гусева И.А., Чанышев М.Д., Торгашина А.В., Власенко Н.В., Хван Ю.И., Самаркина Е.Ю., Шабатина М.В., Хафизов К.Ф.</copyright-holder><copyright-holder xml:lang="en">Guseva I.A., Chanyshev M.D., Torgashina A.V., Vlasenko N.V., Khvan Y.I., Samarkina E.Y., Shabatina M.V., Khafizov K.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1666">https://mrj.ima-press.net/mrj/article/view/1666</self-uri><abstract><p>По данным зарубежной литературы, аллели HLA могут быть связаны с предрасположенностью к развитию синдрома Шегрена (СШ), в первую очередь с продукцией аутоантител к антигенам Ro/SSA (анти-Ro/SSA) и La/SSB (анти-La/SSB). В России подобные исследования не проводились.</p><p>Цель исследования – изучить взаимосвязь аллелей генов HLA-A, HLA-B, HLA-C, HLA-DRB1 с риском развития СШ и продукцией анти-Ro/SSA и анти-La/SSB.</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 80 пациентов с СШ или болезнью Шегрена (БШ). Все больные соответствовали критериям СШ ACR/EULAR 2016 г. У 67 (83,8%) пациентов выявлены анти-Ro/SSA и анти-La/SSB, причем у 37 имелась комбинация анти-Ro/SSA/анти-La/SSB, у 30 – только анти-Ro/SSA, и у 13 эти антитела не обнаружены. Контрольную группу составили 160 здоровых доноров крови без аутоиммунных заболеваний (АИЗ) и отягощенной наследственности по АИЗ, сопоставимых по полу и возрасту с группой больных.</p><p>Высокопроизводительное секвенирование аллелей генов HLA-A, HLA-B, HLA-C, HLA-DRB1 проводилось на платформе Illumina MiSeq с использованием набора реагентов MiSeq Reagent Kit v3. Для амплификации экзонов генов HLA-A, HLA-B, HLA-C, HLA-DRB1 использовались 56 специально разработанных праймеров, содержащих на 5’-концах адаптеры Illumina для последующей индексации. Статистическая обработка данных, включающая сравнение частоты аллелей HLA в группе пациентов с СШ/БШ и в контрольной группе, проводилась в программной среде Python с использованием библиотек NumPy, Pandas, Scikit-learn.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. В группе больных по сравнению с контрольной группой было отмечено увеличение частоты аллеля HLA-A*01:01:01 (отношение шансов, ОШ 3,28; 95% доверительный интервал, ДИ 1,90–5,67; p&lt;0,001), аллеля B*08:01:01 (ОШ 5,41; 95% ДИ 3,00–9,82; p&lt;0,001), аллеля C*07:01:01 (ОШ 5,12; 95% ДИ 2,57–10,19; p&lt;0,001), аллеля DRB1*03:01:01 (ОШ 3,78; 95% ДИ 2,27–6,30; p&lt;0,001). Кроме того, все 2-, 3- и 4-аллельные комбинации значительно чаще встречались в группе больных по сравнению с контрольной группой. Наиболее статистически значимыми комбинациями аллелей как маркеров риска развития СШ являлись 2-аллельный гаплотип B*08:01:01-DRB1*03:01:01 (ОШ 6,65; 95% ДИ 3,37–13,14; p&lt;0,001) аллеля DRB1*03:01:01 (ОШ 3,78; 95% ДИ 2,27–6,30; p&lt;0,001). Кроме того, все 2-, 3- и 4-аллельные комбинации значительно чаще встречались в группе больных по сравнению с контрольной группой. Наиболее статистически значимыми комбинациями аллелей как маркеров риска развития СШ являлись 2-аллельный гаплотип B*08:01:01-DRB1*03:01:01 (ОШ 6,65; 95% ДИ 3,37–13,14; p&lt;0,001) и 4-аллельный гаплотип A*01:01-B*08:01-C*07:01-DRB1*03:01 (ОШ 6,05; 95% ДИ 2,71–13,51; p&lt;0,001). Наиболее значимая взаимосвязь продукции анти-Ro/SSA/анти-La/SSB была выявлена с гаплотипами B*08:01:01-DRB1*03:01:01 (ОШ 9,50; 95% ДИ 4,16–21,70; p&lt;0,001) и A*01:01:0-B*08:01:01-C*07:01:01-DRB1*03:01:01 (ОШ 7,20; 95% ДИ 2,81–18,43; p&lt;0,001). У 30 больных с продукцией только анти-Ro/SSA ассоциация с указанными гаплотипами была менее выражена, хотя и оставалась высокой.</p><p>Малая выборка больных без анти-Ro/SSA и анти-La/SSB (n=13) не позволила выявить статистически значимые ассоциации с аллелями/гаплотипами HLA.</p></sec><sec><title>Заключение</title><p>Заключение. Установлена статистически значимая ассоциация ряда аллелей/гаплотипов HLA, входящих в предковый гаплотип 8.1 (AH8.1), как маркеров предрасположенности к СШ и продукции анти-Ro/SSA и анти-La/SSB.</p></sec></abstract><trans-abstract xml:lang="en"><p>Literature data suggest that HLA alleles may be associated with the development of Sjögren's syndrome (SS) and the production of autoantibodies against the Ro/SSA and La/SSB antigens. However, such studies have not been conducted in Russia.</p><sec><title>Objective</title><p>Objective: to study the association between alleles of the HLA-A, HLA-B, HLA-C and HLA-DRB1 genes and the risk of developing SS and the production of autoantibodies.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 80 patients with SS or Sjögren's disease (SD). All patients met the ACR/EULAR criteria, 2016. AntiRo/SSA and anti-La/SSB autoantibodies were detected in 67 patients (83.8%), 37 patients had the combination anti-Ro/SSA/anti-La/SSB, 30 patients had only anti-Ro/SSA, and 13 patients did not have these antibodies. The control group consisted of 160 healthy blood donors without autoimmune diseases and without a family history of autoimmune diseases, who were comparable in gender and age to the patient group. High-throughput sequencing of the alleles of the HLA-A, HLA-B, HLA-C and HLA-DRB1 genes was performed on the Illumina MiSeq platform using the MiSeq Reagent Kit v3. To amplify the exons of the HLA-A, HLA-B, HLA-C and HLA-DRB1 genes, 56 specially designed primers containing Illumina adapters at the 5’ ends for subsequent indexing were used. Statistical data processing, including comparison of the frequencies of HLA alleles in the group of patients with SS/SD and in the control group, was performed in the Python software environment using the Numpy, Pandas and scikit-learn libraries.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. In the group of patients compared to the control group we observed an increase in frequency for the alleles HLA-A*01:01:01 (OR=3.28, 95% CI [1.90–5.67], p &lt;0.001), B*08:01:01 (OR=5.41, 95% CI [3.00–9.82], p&lt;0.001), C*07:01:01 (OR=5.12, 95% CI [2.57– 10.19], p&lt;0.001). In addition, all 2-, 3- and 4-allele combinations were significantly more frequent in the patient group compared to the controls. The most significant combinations of alleles as risk markers for the development of SS were the 2-allele haplotype B*08:01:01-DRB1*03:01:01 (OR=6.65, 95% CI [3.37–13.14], p&lt;0.001) and the 4-allele haplotype A*01:01- B*08:01-C*07:01-DRB1*03:01 (OR=6.05, 95% CI [2.71–13.51], p &lt;0.001). The most significant correlation between the production of two autoantibodies anti-Ro/SSA/anti-La/SSB was found for the haplotypes B*08:01:01-DRB1*03:01:01 (OR=9.50, 95% CI [4.16–21.70], p&lt;0.001) and A*01:01:01-B*08:01:01-C*07:01:01-DRB1*03:01:01 (OR=7.20, 95% CI [2.81–18.43], p &lt;0.001). In the group of 30 patients who only produced anti-Ro/SSA, the association with the above-mentioned haplotypes was less pronounced, although it remained high. Small sample of patients without anti-Ro/SSA and anti-La/SSB (13 patients), did not allow to determine statistically significant associations with HLA alleles/haplotypes.</p></sec><sec><title>Conclusion</title><p>Conclusion. A statistically significant association was found between several HLA alleles/haplotypes belonging to ancestral haplotype 8.1 (AH 8.1) as markers of susceptibility to SS and the production of Ro/SSA and La/SSB autoantibodies.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Шегрена</kwd><kwd>синдром Шегрена</kwd><kwd>аутоантитела к Ro/SSA</kwd><kwd>аутоантитела к La/SSB</kwd><kwd>HLA</kwd><kwd>аллели HLA</kwd><kwd>гаплотипы HLA</kwd><kwd>предковый гаплотип 8.1 (AH8.1)</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Sjögren's disease</kwd><kwd>Sjögren's syndrome</kwd><kwd>Ro/SSA autoantibodies</kwd><kwd>La/SSB autoantibodies</kwd><kwd>HLA</kwd><kwd>HLA alleles</kwd><kwd>HLA haplotypes</kwd><kwd>ancestral haplotype 8.1 (AH8.1)</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья подготовлена в рамках государственного задания по теме № 1021051402790-6.</funding-statement><funding-statement xml:lang="en">The article was prepared within the framework of the state assignment on topic № 1021051402790-6.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Сафонова ТН, Васильев ВИ, Лихванцева ВГ. Синдром Шегрена: Руководство для врачей. Москва: Московский государственный университет имени М.В.Ломоносова; 2013. 600 с.</mixed-citation><mixed-citation xml:lang="en">Safonova TN, Vasil'ev VI, Likhvantseva VG. Sjögren's Syndrome: A Guide for Physicians. Moscow: Lomonosov Moscow State University; 2013. 600 p</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Negrini S, Emmi G, Greco M, et al. Sjögren's syndrome: a systemic autoimmune disease. Clin Exp Med. 2022 Feb;22(1):9-25. doi: 10.1007/s10238-021-00728-6.</mixed-citation><mixed-citation xml:lang="en">Negrini S, Emmi G, Greco M, et al. Sjögren's syndrome: a systemic autoimmune disease. Clin Exp Med. 2022 Feb;22(1):9-25. doi: 10.1007/s10238-021-00728-6.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Thorlacius GE, Björk A, Wahren-Herlenius M, et al. Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies. Nat Rev Rheumatol. 2023 May; 19(5):288-306. doi: 10.1038/s41584-023-00932-6.</mixed-citation><mixed-citation xml:lang="en">Thorlacius GE, Björk A, Wahren-Herlenius M, et al. Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies. Nat Rev Rheumatol. 2023 May; 19(5):288-306. doi: 10.1038/s41584-023-00932-6.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Björk A, Mofors J, Wahren-Herlenius M et al. Environmental factors in the pathogenesis of primary Sjögren's syndrome. J InternMed. 2020 May;287(5):475-492. doi: 10.1111/joim.13032. Epub 2020 Feb 27.</mixed-citation><mixed-citation xml:lang="en">Björk A, Mofors J, Wahren-Herlenius M et al. Environmental factors in the pathogenesis of primary Sjögren's syndrome. J InternMed. 2020 May;287(5):475-492. doi: 10.1111/joim.13032. Epub 2020 Feb 27.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mariette X, Gozlan J, Clerc D, et al. Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjögren's syndrome. Am J Med. 1991 Mar;90(3):286-94.</mixed-citation><mixed-citation xml:lang="en">Mariette X, Gozlan J, Clerc D, et al. Detection of Epstein-Barr virus DNA by in situ hybridization and polymerase chain reaction in salivary gland biopsy specimens from patients with Sjögren's syndrome. Am J Med. 1991 Mar;90(3):286-94.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjögren's syndrome. Arthritis Rheum. 2004 Sep;50(9): 2897-902. doi: 10.1002/art.20463.</mixed-citation><mixed-citation xml:lang="en">Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjögren's syndrome. Arthritis Rheum. 2004 Sep;50(9): 2897-902. doi: 10.1002/art.20463.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Perez P, Anaya JM, Aguilera S, et al. Gene expression and chromosomal location for susceptibility to Sjögren's syndrome. J Autoimmun. 2009 Sep;33(2):99-108. doi: 10.1016/j.jaut.2009.05.001.</mixed-citation><mixed-citation xml:lang="en">Perez P, Anaya JM, Aguilera S, et al. Gene expression and chromosomal location for susceptibility to Sjögren's syndrome. J Autoimmun. 2009 Sep;33(2):99-108. doi: 10.1016/j.jaut.2009.05.001.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yin J, Zheng J, Deng F, et al. Gene Expression Profiling of Lacrimal Glands Identifies the Ectopic Expression of MHC II on Glandular Cells as a Presymptomatic Feature in a Mouse Model of Primary Sjögren's Syndrome. Front Immunol. 2018 Oct 31; 9:2362. doi: 10.3389/fimmu.2018.02362.</mixed-citation><mixed-citation xml:lang="en">Yin J, Zheng J, Deng F, et al. Gene Expression Profiling of Lacrimal Glands Identifies the Ectopic Expression of MHC II on Glandular Cells as a Presymptomatic Feature in a Mouse Model of Primary Sjögren's Syndrome. Front Immunol. 2018 Oct 31; 9:2362. doi: 10.3389/fimmu.2018.02362.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009 Jan;54(1):15-39. doi: 10.1038/jhg.2008.5</mixed-citation><mixed-citation xml:lang="en">Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009 Jan;54(1):15-39. doi: 10.1038/jhg.2008.5</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fye KH, Terasaki PI, Michalski JP, et al. Relationshipp of HLA-Dw3 and HLA-B8 to Sjögren's syndrome. Arthritis Rheum. 1978 Apr;21(3):337-42. doi: 10.1002/art.1780210308.</mixed-citation><mixed-citation xml:lang="en">Fye KH, Terasaki PI, Michalski JP, et al. Relationshipp of HLA-Dw3 and HLA-B8 to Sjögren's syndrome. Arthritis Rheum. 1978 Apr;21(3):337-42. doi: 10.1002/art.1780210308.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kruskall MS. The major histocompatibility complex: the value of extended haplotypes in the analysis of associated immune diseases and disorders. Yale J Biol Med. 1990 Sep-Oct;63(5):477-86</mixed-citation><mixed-citation xml:lang="en">Kruskall MS. The major histocompatibility complex: the value of extended haplotypes in the analysis of associated immune diseases and disorders. Yale J Biol Med. 1990 Sep-Oct;63(5):477-86</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev. 1999 Feb;167:257-74. doi: 10.1111/j.1600-065x.1999.tb01398.x.</mixed-citation><mixed-citation xml:lang="en">Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev. 1999 Feb;167:257-74. doi: 10.1111/j.1600-065x.1999.tb01398.x.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Shiina T, Kulski JK. HLA Genetics for the Human Diseases. Adv Exp Med Biol. 2024:1444:237-258. doi: 10.1007/978-981-99-9781-7_16.</mixed-citation><mixed-citation xml:lang="en">Shiina T, Kulski JK. HLA Genetics for the Human Diseases. Adv Exp Med Biol. 2024:1444:237-258. doi: 10.1007/978-981-99-9781-7_16.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gambino CM, Aiello A, Accardi G. et al. Autoimmune diseases and 8.1 ancestral haplotype: An update. HLA. 2018 Sep;92(3): 137-143. doi: 10.1111/tan.13305.</mixed-citation><mixed-citation xml:lang="en">Gambino CM, Aiello A, Accardi G. et al. Autoimmune diseases and 8.1 ancestral haplotype: An update. HLA. 2018 Sep;92(3): 137-143. doi: 10.1111/tan.13305.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mehra NK, Kaur G. MHC-based vaccination approaches: progress and perspectives. Expert Rev Mol Med. 2003 Feb 24;5(7):1-17. doi: 10.1017/S1462399403005957.</mixed-citation><mixed-citation xml:lang="en">Mehra NK, Kaur G. MHC-based vaccination approaches: progress and perspectives. Expert Rev Mol Med. 2003 Feb 24;5(7):1-17. doi: 10.1017/S1462399403005957.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cruz-Tapias P, Rojas-Villarraga A, MaierMoore S, Anaya JM. HLA and Sjögren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012 Feb;11(4):281-7. doi: 10.1016/j.autrev.2011.10.002.</mixed-citation><mixed-citation xml:lang="en">Cruz-Tapias P, Rojas-Villarraga A, MaierMoore S, Anaya JM. HLA and Sjögren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012 Feb;11(4):281-7. doi: 10.1016/j.autrev.2011.10.002.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tzioufas AG, Wassmuth R, Dafni UG, et al. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study. Ann Rheum Dis. 2002 May;61(5):398-404. doi: 10.1136/ard.61.5.398.</mixed-citation><mixed-citation xml:lang="en">Tzioufas AG, Wassmuth R, Dafni UG, et al. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study. Ann Rheum Dis. 2002 May;61(5):398-404. doi: 10.1136/ard.61.5.398.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Shiboski CH, Shiboski SC, Seror R, et al. International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and datadriven methodology involving three international patient cohorts. Ann Rheum Dis. 2017 Jan;76(1):9-16. doi: 10.113619.</mixed-citation><mixed-citation xml:lang="en">Shiboski CH, Shiboski SC, Seror R, et al. International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and datadriven methodology involving three international patient cohorts. Ann Rheum Dis. 2017 Jan;76(1):9-16. doi: 10.113619.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Bolstad AI, Wassmuth R, Haga HJ, Jonsson R. HLA markers and clinical characteristics in Caucasians with primary Sjögren's syndrome. J Rheumatol. 2001 Jul;28(7):1554-62.</mixed-citation><mixed-citation xml:lang="en">Bolstad AI, Wassmuth R, Haga HJ, Jonsson R. HLA markers and clinical characteristics in Caucasians with primary Sjögren's syndrome. J Rheumatol. 2001 Jul;28(7):1554-62.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Solberg OD, Mack SJ, Lancaster AK, et al. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol. 2008 Jul;69(7):443-64. doi: 10.1016/j.humimm.2008.05.001.</mixed-citation><mixed-citation xml:lang="en">Solberg OD, Mack SJ, Lancaster AK, et al. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol. 2008 Jul;69(7):443-64. doi: 10.1016/j.humimm.2008.05.001.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Doherty PC, Zinkernagel RM. A biological role for the major histocompatibility antigens. Lancet. 1975 Jun 28;1(7922):1406-9. doi: 10.1016/s0140-6736(75)92610-0.</mixed-citation><mixed-citation xml:lang="en">Doherty PC, Zinkernagel RM. A biological role for the major histocompatibility antigens. Lancet. 1975 Jun 28;1(7922):1406-9. doi: 10.1016/s0140-6736(75)92610-0.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Хамаганова ЕГ, Леонов ЕА, Абдрахимова АР и др. HLA генетическое разнообразие русской популяции, выявленное методом секвенирования следующего поколения. Медицинская иммунология. 2021; 23(3):509-522.</mixed-citation><mixed-citation xml:lang="en">Khamaganova EG, Leonov EA, Abdrakhimova AR, et al. HLA diversity in the Russian population assessed by next generation sequencing. Meditsinskaya immunologiya. 2021; 23(3):509-522. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Candore G, Lio D, Colonna Romano G, Caruso C. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev. 2002 Feb;1(1-2):29-35. doi: 10.1016/s1568-9972(01)00004-0.</mixed-citation><mixed-citation xml:lang="en">Candore G, Lio D, Colonna Romano G, Caruso C. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev. 2002 Feb;1(1-2):29-35. doi: 10.1016/s1568-9972(01)00004-0.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Matzaraki V, Kumar V, Wijmenga C, Zhernakova A. The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol. 2017 Apr 27;18(1):76. doi: 10.1186/s13059-017-1207-1</mixed-citation><mixed-citation xml:lang="en">Matzaraki V, Kumar V, Wijmenga C, Zhernakova A. The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Genome Biol. 2017 Apr 27;18(1):76. doi: 10.1186/s13059-017-1207-1</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
